- Some experts who have received Johnson & Johnson’s single-use vaccine supplement it with Pfizer or Modenana.
- They did it to provide extra protection from the rapidly spreading coronavirus delta variant, they said.
- The FDA and CDC do not recommend additional vaccinations. after J&J vaccination or something else
- See more stories on the Business Insider page.
Some experts who have received Johnson & Johnson’s single-use vaccines are testing additional Modernna or Pfizer vaccinations. to prevent the rapid spread of delta coronavirus
Officials do not recommend post-vaccination against J&J vaccines or other vaccines. And two experts say everyone should wait for more information.
Angela Rasmussen, a virologist at the University of Saskatchewan, Canada, said on Twitter on Tuesday that she had received the Pfizer vaccine to “turn off”; the J&J vaccine she received in April.
Rasmussen said the increase in the UK delta variable — More than 95% of new infections are caused by Delta. — Demonstrates the “great importance” of vaccinating as many people as possible.
Rasmussen said we don’t know whether additional vaccination after the J&J injection increases the protection against the variant. And the Food and Drug Administration (FDA) or the CDC did not make any recommendations. But it’s likely to work. This is because the booster is compatible with other vaccines. Almost every kind used, she said.
“We shouldn’t wait to give advice on this,” she said.
Rasmussen encourages people who have previously received J&J, especially those who live in communities with low vaccination rates. Talk to your health care provider about getting more medication.
Dr Anthony Fauci, Chief Medical Advisor to President Joe Biden, said Wednesday that The Delta variant accounts for more than 20% of all new infections in the United States and is the “biggest threat” to the nation’s efforts to eradicate COVID-19.
There is no data on how well the J&J vaccine works compared to the Delta variant. According to the Centers for Disease Control and Prevention (CDC), more than 9 million Americans receive a single dose of the vaccine.
Read more: Experts explain why revolutionary mRNA technology for COVID-19 vaccine could be the answer to incurable diseases, heart attacks and even snake bites: ‘The possibilities are endless’
Jason Gallagher, a clinical professor of infectious diseases at Temple University’s School of Pharmacy, told Reuters on Monday he received the J&J vaccine in a trial in November. and recently received Pfizer-BioNTech’s COVID-19 vaccine.
Gallagher said he was concerned about the recommended data. A single Pfizer or AstraZeneca vaccine is only 33% effective against COVID-19. that shows symptoms caused by delta variables “So I jumped,” he said.
Professor Peter Hotez, Dean of the National School of Tropical Medicine at Baylor College of Medicine. said in a tweet on Thursday that A second J&J dose or another shot of Pfizer or Moderna vaccine could protect against a wider range of variables, “but we need CDC-FDA information and advice.”
Dr. John Beigel, deputy director of clinical research at the National Institute for Allergy and Infectious Disease (NIAID), told Reuters on Monday that J&J recipients should wait for more information.